This post‐translational modification promotes PRMT1‐vimentin interaction and subsequent asymmetric dimethylation (aDMA) of vimentin at arginine (R64), driving cytoskeletal remodeling and metastatic competence in cancer cells (Figure 7). Here, PRMT1 is linked to cancer.